Cameron W Brennan

List of Publications by Year in Descending Order

155 papers	47,200 citations	77 h-index	159 g-index
159 ext. papers	54,950 ext. citations	14.4 avg, IF	7.99 L-index

#	Paper	IF	Citations
155	Quiescent human glioblastoma cancer stem cells drive tumor initiation, expansion, and recurrence following chemotherapy.. *Developmental Cell*, **2022**, 57, 32-46.e8	10.2	2
154	The Evolution of 5-Aminolevulinic Acid Fluorescence Visualization: Time for a Headlamp/Loupe Combination.. *World Neurosurgery*, **2021**, 159, 136-136	2.1	0
153	Salvage resection of recurrent previously irradiated brain metastases: tumor control and radiation necrosis dependency on adjuvant re-irradiation. *Journal of Neuro-Oncology*, **2021**, 155, 277-286	4.8	2
152	PRMT6 methylation of RCC1 regulates mitosis, tumorigenicity, and radiation response of glioblastoma stem cells. *Molecular Cell*, **2021**, 81, 1276-1291.e9	17.6	9
151	The effect of surgery on radiation necrosis in irradiated brain metastases: extent of resection and long-term clinical and radiographic outcomes. *Journal of Neuro-Oncology*, **2021**, 153, 507-518	4.8	7
150	Durable 5-year local control for resected brain metastases with early adjuvant SRS: the effect of timing on intended-field control. *Neuro-Oncology Practice*, **2021**, 8, 278-289	2.2	5
149	Mechanisms of stearoyl CoA desaturase inhibitor sensitivity and acquired resistance in cancer. *Science Advances*, **2021**, 7,	14.3	8
148	Cerebrospinal fluid diversion for leptomeningeal metastasis: palliative, procedural and oncologic outcomes. *Journal of Neuro-Oncology*, **2021**, 154, 301-313	4.8	1
147	SURG-03. The effect of surgery on radiation necrosis in irradiated brain metastases: extent of resection and long-term clinical and radiographic outcomes. *Neuro-Oncology Advances*, **2021**, 3, iii23-iii24	0.9	78
146	Risk of tract recurrence with stereotactic biopsy of brain metastases: an 18-year cancer center experience. *Journal of Neurosurgery*, **2021**, 1-7	3.2	1
145	Defining phenotypic and functional heterogeneity of glioblastoma stem cells by mass cytometry. *JCI Insight*, **2021**, 6,	9.9	4
144	Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions. *Acta Neuropathologica Communications*, **2020**, 8, 186	7.3	9
143	Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells. *Cell*, **2020**, 181, 1643-1660.e17	56.2	200
142	Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma. *Oncologist*, **2020**, 25, e1837-e1845	5.7	9
141	Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model. *Clinical Cancer Research*, **2020**, 26, 147-158	12.9	34
140	Cell Lineage-Based Stratification for Glioblastoma. *Cancer Cell*, **2020**, 38, 366-379.e8	24.3	23
139	LY6K promotes glioblastoma tumorigenicity via CAV-1-mediated ERK1/2 signaling enhancement. *Neuro-Oncology*, **2020**, 22, 1315-1326	1	7

138	Temporal Lobe Necrosis in Head and Neck Cancer Patients after Proton Therapy to the Skull Base. *International Journal of Particle Therapy*, **2020**, 6, 17-28	1.5	8
137	F-Fluorocholine PET uptake correlates with pathologic evidence of recurrent tumor after stereotactic radiosurgery for brain metastases. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 1446-1457	8.8	9
136	Molecular Engineering of Ultrasmall Silica Nanoparticle-Drug Conjugates as Lung Cancer Therapeutics. *Clinical Cancer Research*, **2020**, 26, 5424-5437	12.9	9
135	Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma. *Neuro-Oncology*, **2020**, 22, 1742-1756	1	7
134	Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors. *OncoImmunology*, **2019**, 8, e1655360	7.2	40
133	Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. *Nature*, **2019**, 565, 654-658	50.4	214
132	EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma. *Journal of Neuro-Oncology*, **2019**, 142, 337-345	4.8	18
131	Sequencing and curation strategies for identifying candidate glioblastoma treatments. *BMC Medical Genomics*, **2019**, 12, 56	3.7	5
130	Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer. *Cancer Discovery*, **2019**, 9, 756-777	24.4	13
129	Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. *Clinical Cancer Research*, **2019**, 25, 5537-5547	12.9	48
128	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. *Nature Genetics*, **2019**, 51, 202-206	36.3	1435
127	Incidence of Prolonged Systemic Steroid Treatment after Surgery for Acoustic Neuroma and Its Implications. *Journal of Neurological Surgery, Part B: Skull Base*, **2018**, 79, 559-568	1.5	
126	Intracranial metastasis in fibrolamellar hepatocellular carcinoma. *Pediatric Blood and Cancer*, **2018**, 65, e26919	3	3
125	Thalamic Glioblastoma: Clinical Presentation, Management Strategies, and Outcomes. *Neurosurgery* , **2018**, 83, 76-85	3.2	23
124	Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE. *Clinical Cancer Research*, **2018**, 24, 737-743	12.9	97
123	Genome-wide methylomic and transcriptomic analyses identify subtype-specific epigenetic signatures commonly dysregulated in glioma stem cells and glioblastoma. *Epigenetics*, **2018**, 13, 432-448	5.7	25
122	Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence. *Nature Genetics*, **2018**, 50, 62-72	36.3	86
121	Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. *Journal of Clinical Oncology*, **2018**, 36, 1702-1709	2.2	27

120	Metabolic Imaging of the Human Brain with Hyperpolarized C Pyruvate Demonstrates C Lactate Production in Brain Tumor Patients. *Cancer Research*, **2018**, 78, 3755-3760	10.1	127
119	Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. *Neuro-Oncology*, **2017**, 19, 1380-1390	7	20
118	Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. *Cancer Discovery*, **2017**, 7, 1018-1029	24.4	201
117	Prior malignancies in patients harboring glioblastoma: an institutional case-study of 2164 patients. *Journal of Neuro-Oncology*, **2017**, 134, 245-251	4.8	5
116	Clinical outcomes of patients with limited brain metastases treated with hypofractionated (5Gy) conformal radiotherapy. *Radiotherapy and Oncology*, **2017**, 123, 203-208	5.3	12
115	Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML. *Cancer Cell*, **2017**, 32, 506-519.e5	24.3	146
114	FGFR-TACC approaches the first turn in the race for targetable GBM mutations. *Neuro-Oncology*, **2017**, 19, 461-462	1	1
113	Genetic driver mutations define the expression signature and microenvironmental composition of high-grade gliomas. *Glia*, **2017**, 65, 1914-1926	9	37
112	EGFR and PDGFRA co-expression and heterodimerization in glioblastoma tumor sphere lines. *Scientific Reports*, **2017**, 7, 9043	4.9	21
111	Concurrence of chromosome 6 chromothripsis and glioblastoma metastasis. *Journal of Neurosurgery*, **2017**, 126, 1472-1478	3.2	4
110	Systematic Combinatorial Chimeric Antigen Receptor Therapies to AML. *Blood*, **2017**, 130, 856-856	2.2	
109	Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies. *Cell Reports*, **2016**, 17, 2445-2459	10.6	293
108	Probing the AML Surfaceome for Chimeric Antigen Receptor (CAR) Targets. *Blood*, **2016**, 128, 526-526	2.2	1
107	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. *New England Journal of Medicine*, **2015**, 372, 2481-98	59.2	1828
106	Ultrasmall dual-modality silica nanoparticle drug conjugates: Design, synthesis, and characterization. *Bioorganic and Medicinal Chemistry*, **2015**, 23, 7119-30	3.4	22
105	Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases. *Journal of Neuro-Oncology*, **2015**, 125, 149-56	4.8	165
104	Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. *Science Translational Medicine*, **2015**, 7, 274ra17	17.5	206
103	CLK2 Is an Oncogenic Kinase and Splicing Regulator in Breast Cancer. *Cancer Research*, **2015**, 75, 1516-26	10.1	51

102	Transcriptional diversity of long-term glioblastoma survivors. *Neuro-Oncology*, **2014**, 16, 1186-95	1	55
101	Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. *Nature Genetics*, **2014**, 46, 451-6	36.3	411
100	Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. *Nature Reviews Cancer*, **2014**, 14, 92-107	31.3	383
99	Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. *Clinical Cancer Research*, **2014**, 20, 5023-31	12.9	70
98	Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXP1 to enhance glioblastoma tumorigenicity. *Cancer Research*, **2014**, 74, 1429-39	10.1	53
97	Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 8149-54	11.5	57
96	Outcomes and prognostic factors in women with 1 to 3 breast cancer brain metastases treated with definitive stereotactic radiosurgery. *International Journal of Radiation Oncology Biology Physics*, **2014**, 90, 518-25	4	23
95	Acute inflammatory reactions to hemostatic materials mimicking post-operative intracranial abscess. *Interdisciplinary Neurosurgery: Advanced Techniques and Case Management*, **2014**, 1, 5-7	0.5	4
94	A phase 2 trial of stereotactic radiosurgery boost after surgical resection for brain metastases. *International Journal of Radiation Oncology Biology Physics*, **2014**, 88, 130-6	4	173
93	TRIM3, a tumor suppressor linked to regulation of p21(Waf1/Cip1.). *Oncogene*, **2014**, 33, 308-15	9.2	38
92	Sleeping Beauty mouse models identify candidate genes involved in gliomagenesis. *PLoS ONE*, **2014**, 9, e113489	3.7	16
91	Emerging therapies for glioblastoma. *JAMA Neurology*, **2014**, 71, 1437-44	17.2	123
90	The Somatic Genomic Landscape of Glioblastoma. *Cell*, **2014**, 157, 753	56.2	29
89	Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates. *Acta Neuropathologica*, **2014**, 127, 747-59	14.3	21
88	Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. *Science*, **2013**, 339, 1077-80	33.3	508
87	The somatic genomic landscape of glioblastoma. *Cell*, **2013**, 155, 462-77	56.2	2900
86	A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle **2013**,		1
85	Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. *Clinical Cancer Research*, **2013**, 19, 4951-60	12.9	134

84	CSF-1R inhibition alters macrophage polarization and blocks glioma progression. *Nature Medicine*, **2013**, 19, 1264-72	50.5	1294
83	An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. *Science*, **2013**, 340, 626-30	33.3	855
82	Double minute chromosomes in glioblastoma multiforme are revealed by precise reconstruction of oncogenic amplicons. *Cancer Research*, **2013**, 73, 6036-45	10.1	67
81	A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. *Genes and Development*, **2013**, 27, 1462-72	12.6	50
80	Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. *Oncotarget*, **2013**, 4, 1729-36	3.3	171
79	Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. *Nature Genetics*, **2012**, 44, 1179-81	36.3	552
78	microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma. *Cancer Discovery*, **2012**, 2, 736-49	24.4	90
77	Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. *Cancer Discovery*, **2012**, 2, 458-71	24.4	240
76	Candidate pathways for promoting differentiation or quiescence of oligodendrocyte progenitor-like cells in glioma. *Cancer Research*, **2012**, 72, 4856-68	10.1	49
75	Passenger deletions generate therapeutic vulnerabilities in cancer. *Nature*, **2012**, 488, 337-42	50.4	224
74	MEF promotes stemness in the pathogenesis of gliomas. *Cell Stem Cell*, **2012**, 11, 836-44	18	27
73	A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. *Nature Medicine*, **2012**, 18, 829-34	50.5	847
72	Protein phosphatase 2A mediates dormancy of glioblastoma multiforme-derived tumor stem-like cells during hypoxia. *PLoS ONE*, **2012**, 7, e30059	3.7	47
71	Emerging insights into the molecular and cellular basis of glioblastoma. *Genes and Development*, **2012**, 26, 756-84	12.6	388
70	The role of radiotherapy following gross-total resection of atypical meningiomas. *Journal of Neurosurgery*, **2012**, 117, 679-86	3.2	134
69	Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 3041-6	11.5	381
68	Integrated genomic analyses of ovarian carcinoma. *Nature*, **2011**, 474, 609-15	50.4	5210
67	Recruited cells can become transformed and overtake PDGF-induced murine gliomas in vivo during tumor progression. *PLoS ONE*, **2011**, 6, e20605	3.7	66

66	Stereotactic brain biopsy with a low-field intraoperative magnetic resonance imager. *Operative Neurosurgery*, **2011**, 68, 217-24; discussion 224	1.6	10
65	Magnetic resonance spectroscopy imaging in radiotherapy planning for recurrent glioma. *Medical Physics*, **2011**, 38, 2724-30	4.4	5
64	Neurosurgery for brain tumors: update on recent technical advances. *Current Neurology and Neuroscience Reports*, **2011**, 11, 313-9	6.6	70
63	Genomic profiles of glioma. *Current Neurology and Neuroscience Reports*, **2011**, 11, 291-7	6.6	34
62	Molecular subclassification of diffuse gliomas: seeing order in the chaos. *Glia*, **2011**, 59, 1190-9	9	180
61	Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 19024-9	11.5	81
60	18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers. *Cancer Research*, **2011**, 71, 5164-74	10.1	101
59	Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas. *EMBO Journal*, **2011**, 30, 4084-97	13	110
58	Glioblastoma stem-like cells give rise to tumour endothelium. *Nature*, **2010**, 468, 829-33	50.4	940
57	Identification of DOK genes as lung tumor suppressors. *Nature Genetics*, **2010**, 42, 216-23	36.3	91
56	Integrative genome comparison of primary and metastatic melanomas. *PLoS ONE*, **2010**, 5, e10770	3.7	129
55	PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. *Genes and Development*, **2010**, 24, 2205-18	12.6	152
54	Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. *Genes and Development*, **2010**, 24, 1731-45	12.6	385
53	Mig-6 controls EGFR trafficking and suppresses gliomagenesis. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 6912-7	11.5	91
52	The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 6459-64	11.5	87
51	Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor. *Genes and Development*, **2010**, 24, 2194-206	12.6	63
50	Advanced imaging in brain tumor surgery. *Neuroimaging Clinics of North America*, **2010**, 20, 311-35	3	19
49	Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. *Cell Stem Cell*, **2010**, 6, 141-52	18	408

48	Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. *Cancer Cell*, **2010**, 17, 98-110	24.3	4782
47	PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. *Cancer Cell*, **2010**, 17, 497-509	24.3	189
46	Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. *Cancer Cell*, **2010**, 18, 619-29	24.3	183
45	Loss of imprinting and marked gene elevation are 2 forms of aberrant IGF2 expression in colorectal cancer. *International Journal of Cancer*, **2010**, 127, 568-77	7.5	50
44	The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 9435-40	11.5	196
43	The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. *Genes and Development*, **2009**, 23, 1327-37	12.6	403
42	Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. *PLoS ONE*, **2009**, 4, e7752	3.7	390
41	Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. *Cancer Cell*, **2009**, 16, 44-54	24.3	113
40	An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. *Oncogene*, **2009**, 28, 2773-83	9.2	185
39	PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. *Cell Stem Cell*, **2009**, 4, 226-35	18	647
38	Presurgical evaluation of language using functional magnetic resonance imaging in brain tumor patients with previous surgery. *Neurosurgery*, **2009**, 64, 644-52; discussion 652-3	3.2	36
37	Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature*, **2008**, 455, 1061-8	50.4	5669
36	p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. *Nature*, **2008**, 455, 1129-33	50.4	565
35	Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. *Cancer Cell*, **2008**, 13, 355-64	24.3	101
34	Intraoperative magnetic resonance imaging at 3-T using a dual independent operating room-magnetic resonance imaging suite: development, feasibility, safety, and preliminary experience. *Neurosurgery*, **2008**, 63, 412-24; discussion 424-6	3.2	42
33	Assessment of the language laterality index in patients with brain tumor using functional MR imaging: effects of thresholding, task selection, and prior surgery. *American Journal of Neuroradiology*, **2008**, 29, 528-35	4.4	75
32	Pten and p53 converge on c-Myc to control differentiation, self-renewal, and transformation of normal and neoplastic stem cells in glioblastoma. *Cold Spring Harbor Symposia on Quantitative Biology*, **2008**, 73, 427-37	3.9	93
31	Clinical characterization of human metapneumovirus infection among patients with cancer. *Journal of Infection*, **2008**, 57, 464-71	18.9	45

30	Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. *Science*, **2007**, 318, 287-90	33.3	748
29	Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. *Nature*, **2007**, 447, 966-71	50.4	327
28	Malignant astrocytic glioma: genetics, biology, and paths to treatment. *Genes and Development*, **2007**, 21, 2683-710	12.6	1682
27	MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 20932-7	11.5	1395
26	Common and distinct genomic events in sporadic colorectal cancer and diverse cancer types. *Cancer Research*, **2007**, 67, 10736-43	10.1	59
25	Hypofractionated stereotactic radiotherapy using intensity-modulated radiotherapy in patients with one or two brain metastases. *Stereotactic and Functional Neurosurgery*, **2007**, 85, 82-7	1.6	67
24	High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. *Cancer Cell*, **2006**, 9, 313-25	24.3	353
23	Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. *Cancer Research*, **2006**, 66, 11502-13	10.1	159
22	Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. *Cancer Research*, **2006**, 66, 4065-78	10.1	134
21	Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 5947-52	11.5	463
20	A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma. *Cancer Research*, **2006**, 66, 10815-23	10.1	96
19	Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. *Cell*, **2006**, 125, 1269-81	56.2	352
18	Discordance between functional magnetic resonance imaging during silent speech tasks and intraoperative speech arrest. *Journal of Neurosurgery*, **2005**, 103, 267-74	3.2	49
17	High-resolution genomic profiles of human lung cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 9625-30	11.5	326
16	Common and contrasting genomic profiles among the major human lung cancer subtypes. *Cold Spring Harbor Symposia on Quantitative Biology*, **2005**, 70, 11-24	3.9	18
15	DNA amplification method tolerant to sample degradation. *Genome Research*, **2004**, 14, 2357-66	9.7	73
14	High-resolution global profiling of genomic alterations with long oligonucleotide microarray. *Cancer Research*, **2004**, 64, 4744-8	10.1	122
13	Reprogramming of a melanoma genome by nuclear transplantation. *Genes and Development*, **2004**, 18, 1875-85	12.6	274

12	Balanced-PCR amplification allows unbiased identification of genomic copy changes in minute cell and tissue samples. *Nucleic Acids Research*, **2004**, 32, e76	20.1	52
11	High-resolution characterization of the pancreatic adenocarcinoma genome. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 9067-72	11.5	228
10	Molecular diversity of astrocytes with implications for neurological disorders. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 8384-9	11.5	185
9	Molecular characterization of the tumor microenvironment in breast cancer. *Cancer Cell*, **2004**, 6, 17-32	24.3	1038
8	Comprehensive Genome-Wide Profile of Regional Gains and Losses in Multiple Myeloma Using Array-CGH: The 1q21 Amplification and Potential Role of the BCL-9 Gene in Multiple Myeloma Pathogenesis.. *Blood*, **2004**, 104, 785-785	2.2	4
7	Isolated translocation of Wernicke's area to the right hemisphere in a 62-year-man with a temporo-parietal glioma. *American Journal of Neuroradiology*, **2004**, 25, 130-3	4.4	50
6	Nuclear cloning of embryonal carcinoma cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 13985-90	11.5	88
5	Array comparative genome hybridization for tumor classification and gene discovery in mouse models of malignant melanoma. *Cancer Research*, **2003**, 63, 5352-6	10.1	31
4	A principal components-based method for the detection of neuronal activity maps: application to optical imaging. *NeuroImage*, **2000**, 11, 313-25	7.9	31
3	Concordance between functional magnetic resonance imaging and intraoperative language mapping. *Stereotactic and Functional Neurosurgery*, **1999**, 72, 95-102	1.6	86
2	Extrageniculate vision in hemianopic humans: saccade inhibition by signals in the blind field. *Science* , **1990**, 250, 118-21	33.3	258
1	Saccade preparation inhibits reorienting to recently attended locations.. *Journal of Experimental Psychology: Human Perception and Performance*, **1989**, 15, 673-685	2.6	431